What Foresight Diagnostics does

Foresight Diagnostics is a precision genomics company founded in 2020 and headquartered in Boulder, Colorado, that develops and commercializes ultra-sensitive circulating tumor DNA (ctDNA) liquid biopsy tests for cancer minimal residual disease (MRD) detection and monitoring. The company's core technology, PhasED-Seq (Phased Variant Sequencing), was developed by four Stanford University physician-scientists and detects ctDNA at limits below 0.1 parts per million by tracking two or more single nucleotide variants on the same DNA molecule, claimed to be up to 100x more sensitive than first-generation liquid biopsy methods. The commercial product, Foresight CLARITY, is offered as a laboratory-developed test (LDT) through Foresight's automated, CLIA-certified, and CAP-accredited central laboratory in Boulder, with applications in B-cell lymphoma (DLBCL, follicular lymphoma, classic Hodgkin lymphoma) and exploratory solid tumor indications (NSCLC, breast cancer).

Foresight operates a B2B, sales-led go-to-market model with three revenue streams: diagnostic testing services processed through its CLIA lab, biopharma services including companion diagnostic development and clinical trial execution support (using MRD as enrollment biomarker or surrogate endpoint for event-free survival), and academic research services. The company serves biopharma companies conducting oncology drug development, academic medical centers, and clinical trial sponsors, with named partners including Allogene Therapeutics (ALPHA3 pivotal trial), Bristol Myers Squibb (TRANSFORM/liso-cel study), and Memorial Sloan Kettering Cancer Center. As of acquisition, the company maintained 30+ biopharma and academic research partnerships and had produced 40+ peer-reviewed publications demonstrating clinical validity, including inclusion in NCCN Clinical Practice Guidelines for DLBCL. Pricing is not publicly disclosed and is handled through direct service agreements.

In December 2025, Foresight was acquired by Natera, Inc. in an all-stock transaction valued at $275 million upfront plus up to $175 million in milestone-based earnouts tied to revenue and reimbursement milestones. Following the acquisition, Foresight operates as a wholly-owned subsidiary of Natera, with its PhasED-Seq technology integrated into Natera's Signatera MRD platform and an enhanced test made available for research use, with clinical launch anticipated in 2026.

Name

Foresight Diagnostics

Legal name

Foresight Diagnostics

Website

https://foresight-dx.com

Company type

Private

Founded year

2020

Operating status

Acquired

Headcount range

101–250 employees

Short description

Foresight Diagnostics develops ultra-sensitive liquid biopsy tests for cancer minimal residual disease (MRD) detection using its proprietary PhasED-Seq technology. The Boulder, Colorado-based company serves biopharma firms and academic researchers through its CLIA-certified lab, and was acquired by Natera in December 2025.

Ownership category

akta.pro rank

Product category

Cancer Diagnostics / Liquid Biopsy

NAICS

In-Vitro Diagnostic Substance Manufacturing (325413), Medical Laboratories (621511), Medical and Diagnostic Laboratories (6215), Medical and Diagnostic Laboratories (62151)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071)

akta.pro primary industry

Liquid Biopsy & Minimal Residual Disease (MRD) Precision Testing (HLAAANAG)

akta.pro secondary industries

Oncology Diagnostics (tumor profiling, MRD, liquid biopsy) (HLAAALAE), Liquid Biopsy Biomarkers (ctDNA/ctRNA/CTCs/exosomes) (HLAAAMAH), Immuno-Oncology & Immune Monitoring Biomarkers (TMB, MSI, MRD, immune profiling) (HLAAAMAK)

Keywords

• Liquid biopsy diagnostics
• Minimal residual disease testing
• CtDNA detection technology
• Companion diagnostic development
• Precision genomics oncology

Headquarters

HQ city

Denver

HQ country

United States

HQ region

North America

Offices3 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

1. Diagnostic Testing Services: Foresight Diagnostics provides MRD testing services through its CLIA-certified central laboratory in Boulder, Colorado, offering its Foresight CLARITY liquid biopsy platform for B-cell lymphoma and solid tumor applications.
2. Biopharma Services (CDx Development & Clinical Trial Execution): The company offers companion diagnostic development, clinical trial execution support, and translational research services to biopharma partners, enabling MRD as an endpoint or patient enrollment biomarker in clinical trials.
3. Academic Research Services: Services for academic researchers including access to Foresight CLARITY MRD technology for exploratory research and study design support in oncology.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels6 records

Core offering

Foresight Diagnostics develops and delivers the Foresight CLARITY MRD testing platform, an ultra-sensitive liquid biopsy assay powered by proprietary PhasED-Seq technology that detects circulating tumor DNA at sub-part-per-million levels for minimal residual disease monitoring in cancer patients. The company provides centralized CLIA-certified laboratory testing services for B-cell lymphoma and solid tumor applications, plus companion diagnostic development and clinical trial execution services for biopharma and academic research partners.

Differentiator

Problem solved

Functional benefit

Brands

• PhasED-Seq: Proprietary ctDNA technology platform that tracks phased variants for enhanced detection limits below one part per million, up to 100 times more sensitive than first-generation liquid biopsy methods.
• Foresight CLARITY

Products and services

• Foresight CLARITY MRD Platform — B-cell Lymphoma Fixed, off-the-shelf laboratory-developed test for ultra-sensitive minimal residual disease detection and recurrence monitoring in B-cell lymphoma, including diffuse large B-cell lymphoma (DLBCL/LBCL), follicular lymphoma, and classic Hodgkin lymphoma. The assay detects ctDNA at sub-part-per-million levels and can identify relapse up to 200 days earlier than standard PET/CT imaging. It is intended for use in clinical research, drug development, and post-treatment disease monitoring.
• Foresight CLARITY MRD Platform — Solid Tumors Personalized, ultra-sensitive minimal residual disease assay for exploratory research in solid tumor cancers, including non-small cell lung cancer (NSCLC) and breast cancer. The assay uses patient- and tumor-specific phased variants and has demonstrated improved clinical sensitivity at the post-surgical landmark versus first-generation SNV methods, enabling identification of high-risk post-surgical patients who may benefit from adjuvant therapy.
• Biopharma Services — Companion Diagnostic Development & Clinical Trial Execution Service offering for biopharmaceutical companies that includes companion diagnostic (CDx) development, clinical trial execution support using MRD as an enrollment biomarker and as a clinical trial endpoint, and translational research services. Foresight serves as a research, regulatory, and commercialization partner for biopharma customers.
• Academic Research Services Service offering for academic medical centers and researchers providing access to the Foresight CLARITY MRD platform for exploratory cancer research, ctDNA monitoring studies, and collaborative research programs, including bioinformatics and study design support.

Quantifiable outcome

• Detection limit below 0.1 parts per million — up to 100x more sensitive than first-generation liquid biopsy methods
• +4 more outcomes

Named customers3 records

Segments4 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Four partnerships are on record, tiered core and supporting.

• Allogene TherapeuticscoreStrategic or Co-development PartnerForesight Diagnostics partnered with Allogene Therapeutics to develop a MRD-based in vitro diagnostic (IVD) for use in the ALPHA3 Phase 2 pivotal trial — the first pivotal trial for frontline consolidation in newly diagnosed large B-cell lymphoma patients. Foresight serves as the research, regulatory, and commercialization partner for the companion diagnostic. The company initiated its pivotal Phase 2 ALPHA3 clinical trial in 2024 in partnership with Allogene.
• Bristol Myers SquibbsupportingStrategic or Co-development PartnerBristol Myers Squibb collaborated with Foresight Diagnostics using ctDNA analysis via Foresight CLARITY to predict early response to liso-cel (lisocabtagene maraleucel) in a retrospective analysis of their TRANSFORM Phase 3 study for large B-cell lymphoma. Foresight's technology was used to demonstrate that undetectable ctDNA after liso-cel treatment strongly correlated with longer event-free survival.
• 30+ Academic and Biopharma Research PartnerssupportingStrategic or Co-development PartnerForesight maintains partnerships with more than 30 biopharma and academic researchers. These collaborations span across lymphoma and solid tumor research programs, with partners using Foresight CLARITY for MRD as an enrollment biomarker and as a clinical trial endpoint. Partnerships include translational research interrogating the relationship between MRD and therapeutic response.
• Memorial Sloan Kettering Cancer Center (MSKCC)supportingStrategic or Co-development PartnerMSKCC researchers collaborated with Foresight Diagnostics to present data at ASCO 2024 on ultrasensitive ctDNA MRD monitoring in early-stage NSCLC using PhasED-Seq, demonstrating improved clinical sensitivity at post-surgical landmark vs. first-generation SNV methods.

Scale indicators7 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• Tempus AI: Tempus offers xT, xR, and other oncology testing products spanning tumor profiling, MRD, and multi-modal data. While Tempus is broader than Foresight, its liquid biopsy and biopharma services business directly competes in the same oncology diagnostics and trial-services market.
• Exact Sciences: Exact Sciences offers Oncotype DX, Cologuard, and the Therascreen/Precision Oncology portfolio, including MRD initiatives. As a major publicly traded oncology diagnostics incumbent, it is comparable to Foresight/Natera in the broader oncology testing market.

Direct peers

• NeoGenomics: NeoGenomics provides oncology-focused laboratory services including liquid biopsy and MRD assays through its RaDaR and other oncology tests. It competes with Foresight in providing biopharma trial-support services and clinical oncology diagnostics.
• Personalis: Personalis offers NeXT Personal, a tumor-informed liquid biopsy MRD assay using whole-genome sequencing. It is a direct MRD peer with overlapping biopharma services offerings and similar sensitivity-focused positioning versus first-generation ctDNA assays.
• Caris Life Sciences: Caris offers MI Profile and MI Cancer Seek for comprehensive molecular profiling, plus biopharma services. It competes with Foresight in oncology liquid biopsy testing and biopharma companion diagnostic partnerships.
• Adaptive Biotechnologies: Adaptive Biotechnologies offers clonoSEQ, the FDA-cleared MRD test for lymphoid malignancies. clonoSEQ uses immune receptor sequencing rather than ctDNA but is the dominant blood-based MRD assay in lymphoma, directly competing with Foresight CLARITY in DLBCL.
• Foundation Medicine: Foundation Medicine (a Roche subsidiary) provides FoundationOne Liquid CDx, a comprehensive liquid biopsy assay for tumor profiling and emerging MRD applications. It competes with Foresight CLARITY for biopharma CDx development and oncology testing share.
• GRAIL: GRAIL develops Galleri, a multi-cancer early detection test based on methylation-based ctDNA analysis. While Galleri targets screening rather than MRD, GRAIL's deep ctDNA technology capabilities and biopharma partnerships make it a relevant oncology liquid biopsy peer.
• Guardant Health: Guardant Health offers Guardant360 for tumor profiling and Guardant Reveal for MRD detection, both liquid biopsy products. It competes directly with Foresight/Natera in oncology ctDNA-based testing across biopharma services and clinical diagnostics.
• Natera: Natera operates Signatera, the leading tumor-informed MRD test, and acquired Foresight Diagnostics in December 2025 to integrate PhasED-Seq. Signatera and Foresight CLARITY address the same MRD market across biopharma, academic, and clinical customers with overlapping workflows.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/foresight-diagnostics-inc
• Xx.com/ForesightDx

Revenue estimate

Valuation estimate

Number of profiles

Profiles20 records

Funding overview

Funding rounds3 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Foresight Diagnostics